Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Real-world outcomes highlight unmet needs in R/R germ cell tumors

Darren Feldman • 24 Oct 2026
ESMO 2026
Genitourinary Cancer

Darren Feldman, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a study utilizing an insurance database to examine real-world outcomes for patients with relapsed/refractory germ cell tumors, highlighting the poor median survival and progression-free survival rates for this population. The outcomes, with a median survival of only seven to nine months, emphasize the need for novel therapies in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Darren Feldman

The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
Phase II trial of cabozantinib and nivolumab in non-clear cell renal cell carcinoma
1:27
Phase II trial of cabozantinib and nivolumab in non-clear cell renal cell carcinoma
Darren Feldman • 30 May 2026

Related Videos

The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
0:39
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals